{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T17:34:41Z","timestamp":1789320881314,"version":"build-2803163510"},"reference-count":124,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"unspecified","delay-in-days":134,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Expert Rev. Mol. Med."],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S1462399426100520_sec01\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CAR-T cell gene therapy has advanced from an experimental concept to a standard curative treatment for selected hematologic malignancies. Substantial clinical evidence has established CAR-T therapy as a cornerstone for relapsed\/refractory B-cell malignancies and multiple myeloma, demonstrating durable, long-term remissions. In 2025, the U.S. Food and Drug Administration (FDA) eliminated the Risk Evaluation and Mitigation Strategy (REMS) requirement, reflecting improved clinical management of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Yet, the widespread adoption of these therapies has unveiled a new landscape of long-term and next-generation challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1462399426100520_sec02\" sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review critically analyzes CAR-T therapy\u2019s clinical trajectory and the bioengineering strategies redefining its safety, scalability, and translational potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1462399426100520_sec03\" sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A major hurdle is therapeutic resistance driven by antigen escape, notably through alternative splicing and lineage switching. The emergence of long-term safety signals, specifically secondary T-cell malignancies, has necessitated rigorous surveillance, exemplified by the European Medicines Agency\u2019s (EMA) mandate for lifelong patient monitoring. The therapeutic landscape is further complicated by histopathological and immunological barriers limiting the expansion and persistence of engineered cells. These include deficient T-cell trafficking, an immunosuppressive tumor microenvironment (TME), and antigen heterogeneity, which have historically constrained efficacy in solid tumors. To address these hurdles, the field is leveraging CRISPR-enhanced allogeneic platforms, cytokine-secreting armored CARs (TRUCKs), and logic-gated systems showing early clinical promise.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S1462399426100520_sec04\" sec-type=\"conclusions\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Building on these developments, we hypothesize that CAR-T therapy is undergoing a paradigm shift from single-target cytotoxicity toward a multi-functional, programmable framework capable of overcoming resistance, enhancing safety, and enabling effective penetration of solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/erm.2026.10052","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:28:36Z","timestamp":1778833716000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":1,"title":["A Comprehensive Evaluation of CAR-T Cell Gene Therapy, Tracing its Revolutionary Clinical Breakthroughs and Advancements Towards Next-Generation Engineering"],"prefix":"10.1017","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3471-7073","authenticated-orcid":false,"given":"Melike","family":"Aliciaslan","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01m59r132","id-type":"ROR","asserted-by":"publisher"}],"name":"Akdeniz University: Akdeniz Universitesi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3299-5911","authenticated-orcid":false,"given":"Ezgi","family":"Erbasan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01m59r132","id-type":"ROR","asserted-by":"publisher"}],"name":"Akdeniz University: Akdeniz Universitesi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8379-5678","authenticated-orcid":false,"given":"Salih","family":"Sanlioglu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01m59r132","id-type":"ROR","asserted-by":"publisher"}],"name":"Akdeniz University: Akdeniz Universitesi"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"S1462399426100520_r117","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2025.10"},{"key":"S1462399426100520_r34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152"},{"key":"S1462399426100520_r109","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205103"},{"key":"S1462399426100520_r107","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5"},{"key":"S1462399426100520_r39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01969-y"},{"key":"S1462399426100520_r47","doi-asserted-by":"publisher","DOI":"10.1126\/science.aae0491"},{"key":"S1462399426100520_r14","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70056"},{"key":"S1462399426100520_r114","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.713401"},{"key":"S1462399426100520_r8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583116"},{"key":"S1462399426100520_r24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121945"},{"key":"S1462399426100520_r22","unstructured":"22. FDA. Abecma (idecabtagene vicleucel). 2025 [cited 2026 Feb 12]; Available at https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma."},{"key":"S1462399426100520_r54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1178634"},{"key":"S1462399426100520_r35","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1585238"},{"key":"S1462399426100520_r67","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.108036"},{"key":"S1462399426100520_r119","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00564-w"},{"key":"S1462399426100520_r89","first-page":"287","article-title":"CAR-T regulatory (CAR-Treg) cells: Engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicine"},{"key":"S1462399426100520_r44","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00807-1"},{"key":"S1462399426100520_r76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1421"},{"key":"S1462399426100520_r70","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062315-120245"},{"key":"S1462399426100520_r29","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838"},{"key":"S1462399426100520_r11","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01658-z"},{"key":"S1462399426100520_r72","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02446-2"},{"key":"S1462399426100520_r42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"S1462399426100520_r69","first-page":"147","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nature Reviews: Clinical Oncology"},{"key":"S1462399426100520_r4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02664"},{"key":"S1462399426100520_r91","doi-asserted-by":"crossref","first-page":"SP427","DOI":"10.37765\/ajmc.2023.89391","article-title":"The role of automation in meeting the growing demand for CAR T-cell therapies","volume":"29","author":"Tomtishen","year":"2023","journal-title":"American Journal of Managed Care"},{"key":"S1462399426100520_r83","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0208"},{"key":"S1462399426100520_r106","unstructured":"106. AACR . Daily Takeaways From the AACR Annual Meeting 2025: Tuesday, April 29 2025 [cited 2025 Nov 21]; Available at https:\/\/www.aacr.org\/blog\/2025\/04\/29\/daily-takeaways-from-the-aacr-annual-meeting-2025-tuesday-april-29\/."},{"key":"S1462399426100520_r73","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00860-8"},{"key":"S1462399426100520_r80","unstructured":"80. ASCO. ASCO 2024: New \u2018Armoured\u2019 CAR produces significant responses in patients whose cancers don\u2019t respond to current CAR T cell therapies. 2024 [cited 2025 Nov 20]; Available at https:\/\/ecancer.org\/en\/news\/24820-asco-2024-new-armoured-car-produces-significant-responses-in-patients-whose-cancers-don-t-respond-to-current-car-t-cell-therapies."},{"key":"S1462399426100520_r61","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00189-2"},{"key":"S1462399426100520_r92","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn4116"},{"key":"S1462399426100520_r45","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00979-1"},{"key":"S1462399426100520_r46","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0985-x"},{"key":"S1462399426100520_r21","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-025-00771-z"},{"key":"S1462399426100520_r30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"S1462399426100520_r101","first-page":"e473590","volume-title":"Artificial Intelligence and Machine Learning Innovations to Improve Design and Representativeness in Oncology Clinical Trials","volume":"45","author":"Azenkot","year":"2025"},{"key":"S1462399426100520_r77","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02071-9"},{"key":"S1462399426100520_r95","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0084"},{"key":"S1462399426100520_r56","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S519616"},{"key":"S1462399426100520_r120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490911"},{"key":"S1462399426100520_r112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201855"},{"key":"S1462399426100520_r13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519671"},{"key":"S1462399426100520_r59","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3010162"},{"key":"S1462399426100520_r53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547"},{"key":"S1462399426100520_r98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.07.006"},{"key":"S1462399426100520_r10","first-page":"95","volume-title":"Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy","volume":"15","author":"Hawkins","year":"2021"},{"key":"S1462399426100520_r108","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00375-7"},{"key":"S1462399426100520_r3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169"},{"key":"S1462399426100520_r57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0351"},{"key":"S1462399426100520_r12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41631-w"},{"key":"S1462399426100520_r31","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nature Reviews: Clinical Oncology"},{"key":"S1462399426100520_r105","unstructured":"105. BCT. Focus on CAR-T. 2024 [cited 2025 Nov 21]; Available at https:\/\/www.bloodcancerstoday.com\/conference\/2024-ash-annual-meeting-car-t."},{"key":"S1462399426100520_r28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37630"},{"key":"S1462399426100520_r6","doi-asserted-by":"publisher","DOI":"10.46989\/001c.124277"},{"key":"S1462399426100520_r110","unstructured":"110. Century Therapeutics (2025) Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update [cited 2025 Nov 21]; Available at https:\/\/www.manilatimes.net\/2025\/11\/13\/tmt-newswire\/globenewswire\/century-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-update\/2223133."},{"key":"S1462399426100520_r41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008865"},{"key":"S1462399426100520_r25","unstructured":"25. FDA (2025) FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. [cited 2025 Nov 17]; Available at https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor."},{"key":"S1462399426100520_r88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1723270"},{"key":"S1462399426100520_r118","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01745-8"},{"key":"S1462399426100520_r2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25418"},{"key":"S1462399426100520_r20","unstructured":"20. FDA. FDA approves Obecabtagene Autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. 2025 [cited 2026 Feb 12]; Available at https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute."},{"key":"S1462399426100520_r65","doi-asserted-by":"publisher","DOI":"10.1042\/BST20150291"},{"key":"S1462399426100520_r60","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01744-9"},{"key":"S1462399426100520_r116","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115838"},{"key":"S1462399426100520_r122","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.01.003"},{"key":"S1462399426100520_r93","unstructured":"93. Frellick, M (2022) Dying on the Wait List: Many With Multiple Myeloma Face CAR T Access Issues. [cited 2026 April 18]; Available at https:\/\/www.oncologynewscentral.com\/article\/dying-on-the-wait-list-many-with-multiple-myeloma-face-car-t-access-issues."},{"key":"S1462399426100520_r27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35700"},{"key":"S1462399426100520_r84","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1398902"},{"key":"S1462399426100520_r75","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"S1462399426100520_r78","unstructured":"78. Biosciences, C. Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies. 2025 [cited 2025 Nov 20]; Available at https:\/\/www.globenewswire.com\/news-release\/2025\/11\/03\/3179104\/0\/en\/Caribou-Biosciences-Announces-Positive-Data-from-ANTLER-Phase-1-Trial-Demonstrating-Efficacy-and-Durability-of-Vispa-cel-CB-010-an-Allogeneic-CAR-T-Cell-Therapy-on-Par-with-Autolog.html."},{"key":"S1462399426100520_r63","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04440-0"},{"key":"S1462399426100520_r102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158543"},{"key":"S1462399426100520_r26","unstructured":"26. EMA (2024) CAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin. [cited 2025 Nov 17]; Available at https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-june-2024."},{"key":"S1462399426100520_r50","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027364"},{"key":"S1462399426100520_r68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011"},{"key":"S1462399426100520_r100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.07.044"},{"key":"S1462399426100520_r94","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.70025"},{"key":"S1462399426100520_r115","doi-asserted-by":"publisher","DOI":"10.3389\/frtra.2023.1238535"},{"key":"S1462399426100520_r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.06.016"},{"key":"S1462399426100520_r58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64861-6"},{"key":"S1462399426100520_r52","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020"},{"key":"S1462399426100520_r85","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-024-00749-3"},{"key":"S1462399426100520_r71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199486"},{"key":"S1462399426100520_r15","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02269-w"},{"key":"S1462399426100520_r97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-2323"},{"key":"S1462399426100520_r16","unstructured":"16. FDA. Kymriah (tisagenlecleucel). 2025 [cited 2026 Feb 12]; Available at https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah."},{"key":"S1462399426100520_r104","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00651-6"},{"key":"S1462399426100520_r103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"S1462399426100520_r66","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.07.009"},{"key":"S1462399426100520_r62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005583"},{"key":"S1462399426100520_r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.04.007"},{"key":"S1462399426100520_r36","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"S1462399426100520_r5","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03938-0"},{"key":"S1462399426100520_r64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.003"},{"key":"S1462399426100520_r123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1613622"},{"key":"S1462399426100520_r7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910828"},{"key":"S1462399426100520_r17","unstructured":"17. FDA. Yescarta (axicabtagene ciloleucel). 2025 [cited 2026 Feb 12]; Available at https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta."},{"key":"S1462399426100520_r111","first-page":"359","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nature Reviews: Clinical Oncology"},{"key":"S1462399426100520_r86","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00482-9"},{"key":"S1462399426100520_r124","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01075-1"},{"key":"S1462399426100520_r32","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2"},{"key":"S1462399426100520_r74","doi-asserted-by":"publisher","DOI":"10.3390\/biom15101407"},{"key":"S1462399426100520_r113","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101079"},{"key":"S1462399426100520_r18","unstructured":"18. FDA. Tecartus (brexucabtagene autoleucel). 2025 [cited 2026 Feb 16]; Available at https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus."},{"key":"S1462399426100520_r121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1615212"},{"key":"S1462399426100520_r9","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-019-0643-y"},{"key":"S1462399426100520_r82","unstructured":"82. Herrick, A and Belur, M (2024) What is Logic-Gating and Why Does It Matter in CAR-T Therapy? [cited 2025 Nov 20]; Available at https:\/\/premier-research.com\/perspectives\/what-is-logic-gating-and-why-does-it-matter-in-car-t-therapy\/."},{"key":"S1462399426100520_r99","doi-asserted-by":"publisher","DOI":"10.1177\/25151355241305856"},{"key":"S1462399426100520_r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"S1462399426100520_r1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711"},{"key":"S1462399426100520_r49","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117252"},{"key":"S1462399426100520_r23","unstructured":"23. EMA. Carvykti (ciltacabtagene autoleucel). 2025 [cited 2026 Feb 12]; Available at https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/carvykti."},{"key":"S1462399426100520_r43","doi-asserted-by":"publisher","DOI":"10.3390\/cells13181596"},{"key":"S1462399426100520_r79","doi-asserted-by":"publisher","DOI":"10.3390\/cells13020146"},{"key":"S1462399426100520_r48","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03442-3"},{"key":"S1462399426100520_r90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910365"},{"key":"S1462399426100520_r37","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-94353-0_27"},{"key":"S1462399426100520_r55","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-025-05329-5"},{"key":"S1462399426100520_r19","unstructured":"19. EMA. Breyanzi (lisocabtagene maraleucel) 2025 [cited 2026 Feb 12]; Available at https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/breyanzi."},{"key":"S1462399426100520_r33","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405"},{"key":"S1462399426100520_r87","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03209-4"},{"key":"S1462399426100520_r96","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594"},{"key":"S1462399426100520_r81","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01509-2"}],"container-title":["Expert Reviews in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1462399426100520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:08:10Z","timestamp":1784272090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1462399426100520\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":124,"alternative-id":["S1462399426100520"],"URL":"https:\/\/doi.org\/10.1017\/erm.2026.10052","relation":{},"ISSN":["1462-3994"],"issn-type":[{"value":"1462-3994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"\u00a9 The Author(s), 2026. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e22"}}